A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Trial Profile

A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Capecitabine; Cisplatin; Fluorouracil
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-062
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 01 Jun 2017 This study has been completed in Spain as per European Clinical Trials Database.
    • 08 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 26 Apr 2017 Planned primary completion date changed from 6 Jun 2020 to 5 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top